Even as Venter was triumphing over the government's gene-mappers in 2000, stock in Celera plummeted as it dawned on investors that the company would have trouble turning DNA data into cash.
Researchers at Rosetta Inpharmatics , a subsidiary of Merck (nyse: MRK - news - people), and elsewhere also see evidence that the gene mappers missed a lot of genes.